Cost-effectiveness of introducing a rotavirus vaccine in developing countries: The case of Mexico
2008

Cost-effectiveness of Rotavirus Vaccine in Mexico

Sample size: 2000000 publication Evidence: high

Author Information

Author(s): Atanacio Valencia-Mendoza, Stefano M Bertozzi, Juan-Pablo Gutierrez, Robbin Itzler

Primary Institution: National Institute of Public Health, Mexico

Hypothesis

The study aims to assess the cost-effectiveness of including the pentavalent rotavirus vaccine in Mexico's national immunisation program.

Conclusion

The rotavirus vaccine is highly cost-effective in Mexico, especially at prices below $15 per dose.

Supporting Evidence

  • Vaccination could prevent 71,464 medical visits, 5,040 hospital admissions, and 612 deaths.
  • The cost per death prevented is estimated at $122,058.
  • The cost per discounted life-year saved is $4,283.
  • At prices below $15 per dose, the vaccine is highly cost-effective.

Takeaway

Vaccinating children against rotavirus can save many lives and reduce hospital visits, making it a smart choice for health programs.

Methodology

A cost-effectiveness model was developed comparing vaccinated and unvaccinated cohorts of children.

Potential Biases

The model may underestimate the true cost-effectiveness of the vaccine due to simplifications.

Limitations

The model does not account for potential vaccine side effects or the impact of illness on parental productivity.

Participant Demographics

The study focuses on a hypothetical birth cohort of 2 million children in Mexico.

Statistical Information

Confidence Interval

95% CI for efficacy against severe gastroenteritis is 88.3 to 100%.

Digital Object Identifier (DOI)

10.1186/1471-2334-8-103

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication